CYP19A1 and neoplasm: Research indicates that ESR1 mutations emerge during both metastatic breast cancer treatment and tumor evolution, and thus the need for a better-personalized treatment with aromatase inhibitor therapy that sequentially monitors and targets ESR1 mutations has been suggested [45].